Year : 2013 | Volume
: 7 | Issue : 3 | Page : 315--321
Melatonin in perioperative medicine: Current perspective
Souvik Maitra, Dalim Kumar Baidya, Puneet Khanna
Department of Anesthesiology and Intensive Care, All India Institute of Medical Sciences, New Delhi, India
M 27, First Floor, Lajpat Nagar 2, New Delhi
Melatonin, a new addition to the armamentarium of anesthesiologist, has some unique properties that are highly desirable in routine peri-operative care. Available clinical data show that preoperative melatonin is as effective as benzodiazepines in reducing preoperative anxiety with minimal action on psychomotor performance and sleep wake cycle. It may be considered as a safe and effective alternative of benzodiazepines as preoperative anxiolytic. It may have opioid sparing effect, may reduce intraocular pressure, and have role in prevention of postoperative delirium. The short-term administration of melatonin is free from significant adverse effects also.
|How to cite this article:|
Maitra S, Baidya DK, Khanna P. Melatonin in perioperative medicine: Current perspective.Saudi J Anaesth 2013;7:315-321
|How to cite this URL:|
Maitra S, Baidya DK, Khanna P. Melatonin in perioperative medicine: Current perspective. Saudi J Anaesth [serial online] 2013 [cited 2019 Nov 14 ];7:315-321
Available from: http://www.saudija.org/text.asp?2013/7/3/315/115316
Preoperative anxiety and postoperative pain are the two major concerns to the anesthesiologists.  Preoperative anxiety may also be associated with postoperative pain. In current practice, benzodiazepines are most commonly used drugs to mitigate preoperative anxiety. However, benzodiazepines may impair psychomotor performance,  cause excessive sedation, and also decrease the duration of the rapid eye movement (REM) sleep.  There is growing interest in the peri-operative use of melatonin predominantly as anxiolytic. In the current review, we discuss perioperative use of melatonin for anxiolysis, analgesia, oxidative stress, and emergence delirium.
Synthesis and Function
Melatonin (N-acetyl-5-methoxytryptamine), discovered about half a century ago,  is a hormone produced chiefly by the pineal gland but also in much smaller amounts by the gastrointestinal tract, retina, platelets, respiratory epithelium, bone marrow, thymus, and skin.  Melatonin is synthesized from tryptophan by a relatively simple step-wise fashion. Tryptophan is initially converted to serotonin; then two more enzymes are involved in melatonin synthesis. Serotonin-N-acetyl transferase is the rate-limiting enzyme in this synthetic pathway.  Regulation of melatonin synthesis is controlled by the light-dark cycle, acting by activation of anterior hypothalamus via the axons of retinal ganglion cells running in the optic nerve and forming the retino-hypothalamic tract.  The O-methylation of N-acetyl-serotonin is a light-dependent process. Serotonin and melatonin synthesis show diurnal rhythms, so that pineal serotonin levels are markedly higher during the day than at night, while the levels of its downstream derivatives, N-acetyl-serotonin and melatonin, peak during the night.
Serum melatonin reaches a peak value (80-150 pg/mL) between midnight and 3 a.m., while its concentration during the day is low (10-20 pg/mL).  The calculated serum half-life of melatonin is about 30-50 minutes. 
The principal physiological action of melatonin is the regulation of circadian rhythm, but serum melatonin level and sleep phase usually does not correlate.  When exogenous melatonin is administered a dose-dependent shift in the timing of sleep occurs. Sleep benefits associated with the use of melatonin are an increase in the total sleep time, sleep efficiency, and stage 2 sleep with a reduction in slow wave sleep.
However, it has also a role in modulation of immune defense responses, body weight and reproduction, tumor growth inhibition, and anti-jetlag effects.  Recently, its antioxidant property has also been established.  Animal studies show that exogenously administered melatonin protects against anesthetic-induced apoptotic neuro-degeneration in the developing rat brain, particularly in the cerebral cortex, and anterior thalamus,  suggesting its neuro-protective function. Melatonin and its analog drugs have hypnotic effects mediated through MT1 and MT2 receptors, especially in the suprachiasmatic nucleus, which acts on the hypothalamic sleep switch cycle. 
Melatonin homeostasis in the perioperative period
Surgery and anesthesia are known to alter the normal circadian pattern of melatonin production from the pineal gland. But available clinical studies on this issue fail to come to a conclusion. Gogenur et al. concluded that patients have significantly increased REM sleep, light sleep, and reduced awake time during the daytime period after surgery compared with before surgery.  They also concluded that disturbances in the circadian regulation of the sleep - wake cycle may be involved in the development of postoperative sleep disturbances. Kδrkelδ et al. found that anesthesia in conjunction with surgery acutely disturbed the normal circadian rhythm of melatonin by delaying the onset of nocturnal melatonin secretion.  Vician et al.  observed higher postoperative nocturnal melatonin levels in patients with colorectal carcinoma undergoing surgery. They suggested that the higher levels were a stress response to the major abdominal surgery due to either the release of gut melatonin into the circulation or to stimulation of pineal melatonin production. However, Nishimura et al.  were not able to demonstrate any significant changes in melatonin secretion in patients who underwent major surgery. Various drugs commonly used in anesthesia are also reported to alter melatonin secretion; benzodiazepines,  non-steroidal anti-inflammatory drugs (NSAIDs),  clonidine,  corticosteroids,  and beta-blockers  decrease plasma levels of melatonin. However, opioids may increase plasma melatonin by stimulating serotonin-N-acetyl transferase.  Clinical studies are not unanimous on melatonin secretion in the perioperative period which may be due to different methods of melatonin estimation, variety of surgical procedures and their complexity, premedications used, differences in anesthetic techniques, and other drugs administered during the perioperative period.
Elliot  found that basal secretion level of melatonin in the day-time period was reduced immediately after surgery and normalized on the second day after surgery. Positive correlation was found between the duration of surgery and the onset of the night-time melatonin peak on the first night following major surgery, suggesting that either the surgical stress or the time in "lights off" in the day-time may have an impact.
Pharmacology of melatonin
Melatonin undergoes extensive first pass metabolism with varying bioavailability.  Melatonin is a highly lipophilic substance with a consequent high volume of distribution  and 70% of plasma melatonin is albumin bound.  Ninety-nine percent is metabolized in the liver to 6-hydroxymelatonin by cytochrome enzymes CYP1A2, conjugated to form sulfates and glucuronides and then, along with the other 1% unchanged, excreted in the urine.  The elimination half-life in humans is approximately 45 minutes. 
Adverse effects of melatonin
Buscemi et al.  in 2006 in a meta-analysis concluded that melatonin is safe for short-term use. They found that most common side-effects of melatonin used in this setting were headache, dizziness, nausea, and drowsiness. Adverse effects of melatonin premedication have been evaluated in detail in a systematic review by Yousaf et al.  Adverse events were evaluated in terms of psychomotor impairment, sedation, disorientation, and amnesia. It was shown that even large dosage of melatonin in healthy volunteers do not cause impairment of fine motor skill, memory, or visual sensitivity.  However, melatonin lacks amnestic effects. Memory recalls both immediately after surgery and 24 hrs postoperative period remain unaffected in patients receiving melatonin. Though melatonin causes more sedation than placebo, the sedation is significantly less than midazolam. They concluded that in comparison with midazolam, melatonin has similar anxiolytic efficacy but less psychomotor impairment and fewer side effects.
Melatonin and preoperative anxiolysis
Anto' n-Tay et al. first demonstrated that exogenously administered melatonin has hypnotic properties in human and it is similar to that seen during intravenous and volatile anesthetic-induced loss of consciousness in terms of electroencephalographic appearance.  Most of the clinical studies which addressed the issue of preoperative anxiolytic effects of melatonin found a significant reduction in anxiety in comparison to placebo. Ionescu et al.  concluded that Melatonin 3 mg can be successfully used as a premedication because of its anxiolytic, analgesic property, and a better recovery profile. Acil et al.  reported that melatonin premedication was associated with preoperative anxiolysis and sedation without postoperative impairment of psychomotor performance. Caumo et al.  found that melatonin and clonidine are comparable in terms of anxiolysis and postoperative morphine consumption and more effective than placebo. They compared 5 mg melatonin and 100 ΅g clonidine with placebo administered in the night before surgery and 1 hour before surgery. However, Capuzzo et al.  found that 10 mg oral melatonin is no better than placebo in reducing preoperative anxiety in elderly patients (age >65 years) undergoing elective surgery. Ismail and Mowafi  concluded that that 10 mg oral melatonin premedication in comparison to placebo for patients undergoing cataract surgery under topical anesthesia has anxiolytic, analgesic, and intraocular pressure reducing effects. In a recent review by Wilhelmsen et al.,  the authors also affirmed the sedative and anxiolytic properties of melatonin. But, they concluded that further studies are needed to establish its analgesic property. Naguib and Samarkandi  compared the perioperative effects of melatonin and midazolam. They concluded that patients who received premedication with either midazolam or melatonin had a significant decrease in anxiety levels and increase in levels of sedation before surgery compared with controls. After surgery, the patients who received midazolam were more sedated and had more psychomotor impairment. Naguib and Samarkandi  studied the effects of different doses of midazolam and melatonin in perioperative period. They found that premedication with 0.05 mg/kg sublingual melatonin was associated with preoperative anxiolysis and sedation without impairment of cognitive and psychomotor skills or affecting the quality of recovery. Preoperative melatonin administration was associated with a faster recovery also along with less emergence excitement than midazolam premedication. The physiologic basis of these clinical findings has also been uncovered. Benzodiazepines, when administered as single large dose or multiple small doses, decrease the duration of REM sleep and thus affecting the qualities of the sleep. In contrast, melatonin, being a natural hormone, does not have any actions on the duration of REM sleep.
Melatonin as an adjunct to anesthetic drugs
Melatonin has hypnotic and anesthetic sparing properties also. Oral premedication with 0.2 mg/kg melatonin significantly reduces the propofol and thiopental doses required for loss of responses to verbal commands and eyelash stimulation.  Animal studies also showed potentiation of anesthetic effects of thiopentone and ketamine.  Intraperitoneal injection of melatonin potentiates isoflurane by reducing its MAC value in rats. 
Does melatonin have analgesic property?
Antinociceptive actions of melatonin have been well demonstrated in various animal studies. Melatonin interacts with multiple receptor sites including opioidergic, benzodiazepinergic, muscarinic, nicotinic, serotonergic, α1 -adrenergic, α2 -adrenergic, and most importantly MT 1 /MT 2 melatonergic receptors present in the dorsal horn of the spinal cord as well in the central nervous system. 
Results from the various clinical studies are not unanimous about the possible analgesic action of melatonin. Caumo et al.  concluded that preoperative 5 mg oral melatonin administered in the night and 1 hour before surgery produced clinically relevant anxiolytic and analgesic effects, especially in the first 24 postoperative hours. The patients who received melatonin required less PCA morphine in the postoperative period. Caumo et al.  also found that 5 mg oral melatonin administered in the night and 1 hour before surgery reduces postoperative pain and decrease postoperative morphine consumption up to 30% in patients undergoing abdominal hysterectomy. Melatonin has also been evaluated as a premedication in reducing tourniquet-related pain and improving analgesia in patients receiving intravenous regional anesthesia (IVRA).  The study concluded that melatonin premedication before IVRA reduced patient anxiety, decreased tourniquet-related pain, and improved perioperative analgesia. In a recent study, Laste et al., found that melatonin significantly reduces inflammatory pain in rats. 
In a recent review,  the authors found that melatonin has analgesic action in all experimental studies regardless of mode of pain induction. They also found that route of administration of melatonin is irrelevant in analgesic action and analgesia is dose dependent. The reviewers also assessed current clinical evidences about the role of melatonin in fibromyalgia and irritable bowel syndrome. They found that in majority of the studies melatonin was effective in relieving pain in the above two conditions. However, the analgesic benefit of melatonin may be due to its hypnotic and anxiolytic action also.
Emergence delirium in children
Samarkandi et al.  compared the perioperative effects of different doses of melatonin and midazolam in children. They found melatonin was as effective as midazolam in alleviating preoperative anxiety in children and associated with a tendency toward faster recovery, lower incidence of excitement postoperatively, and a lower incidence of sleep disturbance at second week postoperatively. Kein et al.  concluded that melatonin is more effective than midazolam in preventing emergence delirium in children and the effect is dose related. Their results showed that the incidence of emergence delirium after 0.05 mg/kg melatonin was 25.0%, incidence after 0.2 mg/kg melatonin was 8.3%, and incidence after 0.4 mg/kg melatonin was 5.4%.
Postoperative delirium: Is melatonin useful?
Derangement of circadian rhythm and increased cortisol secretion after surgery may cause disruption of REM sleep.  Degeneration of the suprachiasmatic nuclei in the geriatric patients may result in lower baseline serum melatonin levels and predisposes them to sleep disturbance in the postoperative period.  Serum melatonin levels decrease after surgery  and after administration of opioids,  which may contribute to disruption of the sleep-wake cycle in the postoperative period.
Available data on the usefulness of melatonin in postoperative delirium is sparse. A couple of case reports  and a study  on this issue are available. In one case, melatonin was used to treat postoperative delirium in a 53-year-old male patient who underwent hip surgery. In the same report, another case was mentioned where melatonin was used to prevent postoperative delirium. A 78-year-old male patient with history of coronary artery disease and transient ischemic attack underwent hip surgery under epidural anesthesia. He had confusion, agitation, and sleep disturbance from third postoperative day onward till seventh post-operative without any concomitant medical problem that time. Three years later, he underwent knee surgery under femoral-sciatic nerve block with sedation. This time he received 2 mg melatonin for 3 days in the night starting after surgery. His postoperative course was uneventful that time.
Sultan  evaluated the role of preoperative sedatives in postoperative delirium. They found that midazolam and clonidine premedication is associated with statistically more postoperative delirium than placebo. However, melatonin premedication (used at a dose of 5mg orally in the night and 90 minutes before surgery) is associated with significantly less delirium than placebo (9.43% vs 32.56%, P = 0.003). The authors also found that melatonin was successful in treating 58% of the patients who developed postoperative delirium. Recently, melatonin has been evaluated for prophylaxis in medical patients with delirium.  The study concluded that low-dose melatonin (at a dose of 0.5 mg at night for 14 days) in elderly medical patients admitted in the emergency department decreases the risk of delirium (12.0% vs. 31.0%, P = 0.014).
Melatonin as an antioxidant
Melatonin maintains mitochondrial function in oxidative stress.  The mechanism of action of melatonin in reducing oxidative stress is complicated and it acts at multiple enzymatic level.  Melatonin scavenges nitric oxide (NO• ) and suppresses the activity of its rate-limiting enzyme, nitric oxide synthase (NOS) and as an indirect antioxidant, stimulates gene expression and activity of superoxide dismutase, thereby inducing the rapid conversion of O2•- to the less toxic H 2 O 2 . Catalase and glutathione peroxidase enzymes are also stimulated by melatonin. Melatonin stimulates the γ-glutamyl cysteine synthase, thereby increasing the level of reduced glutathione (GSH).
Exogenous melatonin was found to decrease mortality in neonates from septic shock.  Kücükakin et al.  studied the effect of melatonin in oxidative and inflammatory stress markers and on perioperative hemodynamic parameters in patients undergoing major vascular surgery. Melatonin administration did not change hemodynamic parameters (mean arterial pressure or pulse rate) during surgery, but oxidative stress parameters (Malondialdehyde and Ascorbic acid) decreased significantly. There was a significant increase in the inflammatory parameters (IL-6 and C- reactive protein) as a consequence of surgery. These were, however, not influenced by melatonin treatment. Treatment of patients undergoing major aortic surgery with melatonin intravenously up to 60 mg in the intraoperative phase was safe and without complications. A previous study in the neonatal surgical population also demonstrated similar findings. 
However, Kücükakin et al.  found that melatonin is ineffective in attenuation oxidative and inflammatory stress in vascular surgery patients. Moreover, its use is associated with more adverse effects. In this study, the patients were randomized to receive either 50 mg melatonin or placebo as infusion for 2 h, starting from the first incision. The aim of the investigators was to establish supra-physiologic levels of plasma melatonin during the surgical intervention, thereby optimizing the antioxidant capacity needed for a possible modification of the oxidative/nitrosative stress response and the degree of myocardial injury. They administered melatonin intravenously to reach higher blood levels when bypassing first-pass metabolism in the liver. However, any effect on the biochemical markers of oxidative stress and inflammation was lacking in patients who received melatonin. The authors concluded that the reason may be that the dose used was low in comparison to previous human clinical study  and they did not infuse melatonin for a longer duration of time.
Pharmacologic preparation and availability
Melatonin is most commonly used in per oral preparation. However, as a premedication before anesthesia and surgery, the sub-lingual route is preferred. A sublingual dose of 0.05 mg/kg body weight before surgery is found to be optimum.
In the USA, melatonin is sold as a dietary supplement but not as a drug so the Food and Drug Administration (FDA) regulations that apply to medications are not applicable to melatonin. Melatonin has been banned from over-the-counter sale in Great Britain, Canada, and many European countries.  However, US FDA has given melatonin an orphan drug status for circadian rhythm disturbance.
The European Medicines Agency has approved Circadin 2 mg (prolonged-release melatonin) for patients aged 55 or over, as monotherapy for the short-term treatment (up to 13 weeks) of primary insomnia characterized by poor quality of sleep. 
In India, melatonin is available in tablet form as a single drug (3 mg) and in a fixed dose combination with alprazolam or vit B6.
Dosing of melatonin in various conditions:
Melatonin is being used in various clinical conditions according to following dosing schedule. 
Benzodiazepine Withdrawal in Elderly with Insomnia: 2 mg controlled-release PO qHS for up to 6 months; taper dose over 6 weeks
Cancer, Adjunctive Therapy: 10-50 mg PO dailyCluster Headache, Prevention: 10 mg PO qHSMigraine Headache: 3 mg PO HSInsomnia: 0.3-5 mg PO qHSDifficulty falling asleep: 5 mg PO 3-4 hour before sleep period × 4 weeksDifficulty maintaining sleep: Use controlled release formulationThrombocytopenia, Chemotherapy-related: 20 mg PO qHSJet Lag: 0.5-5 mg PO HSEastbound- Preflight, early evening dose followed by HS dosing × 4 daysWestbound- Treat HS × 4 days when in new time zoneChronic Fatigue Syndrome: 5 mg PO HSNicotine Withdrawal: 0.3 mg PO 3.5 hours after stopping smokingWinter Depression: 0.125 mg PO BIDPremedication for Surgery: 0.5 mg/kg SLTardive Dyskinesia: 10 mg controlled-release PO qDSleep Disorders (Orphan): Treatment of circadian rhythm sleep disorders in blind people with no light perceptionMelatonin is not recommended during pregnancy or in breast-feeding mothers because of lack of data. 
Available clinical data indicate that melatonin is a safe and effective anxiolytic when used as premedication. It is comparable to midazolam in terms of anxiolysis with less psychomotor impairment. It is also associated with faster recovery with less sedation in the postoperative period. However, the most important physiological benefit of melatonin may be less disruption of the sleep cycle. It may also be used to prevent emergence delirium in pediatric patients and postoperative cognitive dysfunction in elderly patients. However, further studies are required to confirm its analgesic effects.
|1||Warfield CA, Kahn CH. Acute pain management. Programs in U.S. hospitals and experiences and attitudes among U.S. adults. Anesthesiology 1995;83:1090-4.|
|2||Wittenborn JR. Effects of benzodiazepines on psychomotor performance. Br J Clin Pharmacol 1979;7(suppl 1):61-7S.|
|3||Borbe'ly AA, Mattmann P, Loepfe M, Strauch I, Lehmann D. Effect of benzodiazepine hypnotics on all-night sleep EEG spectra. Hum Neurobiol 1985;4:189-94|
|4||Lerner AB, Case JD, Heinzelman RV. Structure of melatonin. J Am Chem Soc 1959;81:6084-5.|
|5||Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: Nature's most versatile biological signal. FEBS J 2006;273:2813-38.|
|6||Klein DC, Coon SL, Roseboom PH, Weller JL, Bernard M, Gastel JA, et al. The melatonin rhythm-generating enzyme: Molecular regulation of serotonin N-acetyltransferase in the pineal gland. Recent Prog Horm Res 1997;52:307-357.|
|7||Carpentieri A, Díaz de Barboza G, Areco V, Peralta López M, Tolosa de Talamoni N. New perspectives in melatonin uses. Pharmacol Res. 2012;65:437-44.|
|8||Dziegiel P, Podhorska-Okolow M, Zabel M. Melatonin: Adjuvant therapy of malignant tumors. Med Sci Monit 2008;14:RA64-70.|
|9||Lane EA, Moss HB. Pharmacokinetics of melatonin in man: First pass hepatic metabolism. J Clin Endocrinol Metab 1985;61:1214-6.|
|10||Shilo L, Dagan Y, Smorjik Y, Weinberg U, Dolev S, Komptel B, et al. Patients in the intensive care unit suffer from severe lack of sleep associated with loss of normal melatonin secretion pattern. Am J Med Sci 1999;317:278-81.|
|11||Waterhouse J, Reilly T, Atkinson G, Edwards B. Jet lag: Trends and coping strategies. Lancet 2007;369:1117-29.|
|12||Reiter RJ, Tan DX, Manchester LC, Pilar Terron M, Flores LJ, Koppisepi S. Medical implications of melatonin: Receptor-mediated and receptor-independent actions. Adv Med Sci 2007;52:11-28.|
|13||Yon JH, Carter LB, Reiter RJ, Jevtovic-Todorovic V. Melatonin reduces the severity of anesthesia-induced apoptotic neurodegeneration in the developing rat brain. Neurobiol Dis 2006;21:522-30.|
|14||Brown GM. Light, melatonin and the sleep-wake cycle. J Psychiatry Neurosci 1994;19:345-53.|
|15||Gögenur I, Wildschiøtz G, Rosenberg J. Circadian distribution of sleep phases after major abdominal surgery. Br J Anaesth 2008;100:45-9.|
|16||Karkela J, Vakkuri O, Kaukinen S, Huang WQ, Pasanen M. The influence of anaesthesia and surgery on the circadian rhythm of melatonin. Acta Anaesthesiol Scand 2002;46:30-6.|
|17||Vician M, Zeman M, Herichova I, Jurani M, Blazicek P, Matis P. Melatonin content in plasma and large intestine of patients with colorectal carcinoma before and after surgery. J Pineal Res 1999;27:164-9.|
|18||Nishimura S, Fujino Y, Shimaoka M, Hagihira S, Taenaka N, Yoshiya I. Circadian secretion patterns of melatonin after major surgery. J Pineal Res 1998;25:73-7.|
|19||McIntyre IM, Norman TR, Burrows GD, Armstrong SM. Alterations to plasma melatonin and cortisol after evening alprazolam administration in humans. Chronobiol Int 1993;10:205-13.|
|20||Murphy PJ, Myers BL, Badia P. Nonsteroidal anti-inflammatory drugs alter body temperature and suppress melatonin in humans. Physiol Behav 1996;59:133-9.|
|21||Munoz-Hoyos A, Fernandez-Garcia JM, Molina-Carballo A, Macias M, Escames G, Ruiz-Cosano C, et al. Effect of clonidine on plasma ACTH, cortisol and melatonin in children. J Pineal Res 2000;29:48-53.|
|22||Demisch L, Demisch K, Nickelsen T. Influence of dexamethasone on nocturnal melatonin production in healthy adult subjects. J Pineal Res 1988;5:317-22.|
|23||Stoschitzky K, Sakotnik A, Lercher P, Zweiker R, Maier R, Liebmann P, et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol 1999;55:111-5.|
|24||Govitrapong P, Pariyanonth M, Ebadi M. The presence and actions of opioid receptors in bovine pineal gland. J Pineal Res 1992;13:124-32.|
|25||Elliott WJ. Circadian variation in the timing of stroke onset: A meta-analysis. Stroke 1998;29:992-6.|
|26||Di WL, Kadva A, Johnston A, Silman R. Varying bioavailability of oral melatonin. N Engl J Med 1997;336:1028-9.|
|27||Pardridge WM, Mietus LJ. Transport of albumin-bound melatonin through the blood-brain barrier. J Neurochem 1980;34:1761-3.|
|28||Cardinali DP, Lynch HJ, Wurtman RJ. Binding of melatonin to human and rat plasma proteins. Endocrinology 1972;91:1213-8.|
|29||Vakkuri O, Leppaluoto J, Kauppila A. Oral administration and distribution of melatonin in human serum, saliva and urine. Life Sci 1985;37:489-95.|
|30||Waldhauser F, Waldhauser M, Lieberman HR, Deng MH, Lynch HJ, Wurtman RJ. Bioavailability of oral melatonin in humans. Neuroendocrinology 1984;39:307-13.|
|31||Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: Meta-analysis. BMJ 2006;332:385-93.|
|32||Yousaf F, Seet E, Venkatraghavan L, Abrishami A, Chung F. Efficacy and safety of melatonin as an anxiolytic and analgesic in the perioperative period: A qualitative systematic review of randomized trials. Anesthesiology 2010;113:968-76.|
|33||Lieberman HR, Waldhauser F, Garfield G, Lynch HJ, Wurtman RJ. Effects of melatonin on human mood and performance. Brain Res 1984;323:201-7.|
|34||Anto'n-Tay F, Diaz JL, Fernandez-Guardiola A. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci 1971;10:841-50.|
|35||Ionescu D, Badescu C, Ilie A, Acalovschi I. Melatonin as premedication for laparoscopic cholecystectomy A double- blind, placebo-controlled study: Scientific letter. SAJAA 2008;57:8-11.|
|36||Acil M, Basgul E, Celiker V, Karagöz AH, Demir B, Aypar U. Perioperative effects of melatonin and midazolam premedication on sedation, orientation, anxiety scores and psychomotor performance. Eur J Anaesthesiol 2004;21:553-7.|
|37||Caumo W, Levandovski R, Hidalgo MP. Preoperative anxiolytic effect of melatonin and clonidine on postoperative pain and morphine consumption in patients undergoing abdominal hysterectomy: A double-blind, randomized, placebo-controlled study. J Pain 2009;10:100-8.|
|38||Capuzzo M, Zanardi B, Schiffino E, Buccoliero C, Gragnaniello D, Bianchi S, et al. Melatonin does not reduce anxiety more than placebo in the elderly undergoing surgery. Anesth Analg 2006;103:121-3.|
|39||Ismail SA, Mowafi HA. Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. Anesth Analg 2009;108:1146-51.|
|40||Wilhelmsen M, Rosenberg J, Gögenur I. [Anxiolytical, analgesic and sedative effects of melatonin in the perioperative phase]. Ugeskr Laeger 2011;173:1424-7.|
|41||Naguib M, Samarkandi AH. Premedication with melatonin: A double-blind, placebo-controlled comparison with midazolam. Br J Anaesth 1999;82:875-80.|
|42||Naguib M, Samarkandi AH. The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: A double-blinded, placebo-controlled study. Anesth Analg 2000;91:473-9.|
|43||Naguib M, Samarkandi A, Moniem MA, Mansour Eel-D, Alshaer AA, Al-Ayyaf HA, et al. Effects of melatonin premedication on propofol and thiopental induction dose-response curves: A prospective, randomized, double blind study. Anesth Analg 2006;103:1448-52.|
|44||Budhiraja S, Singh J. Adjuvant effect of melatonin on anesthesia induced by thiopental sodium, ketamine, and ether in rats. Meth Find Exp Clin Pharmacol 2005;27:697-9.|
|45||Miyoshi H, Ono T, Sumikawa K. Melatonin reduces minimum alveolar concentration for isoflurane in rats. Anesthesiology 2001;95:A-113.|
|46||Srinivasan V, Lauterbach EC, Ho KY, Acuña-Castroviejo D, Zakaria R, Brzezinski A. Melatonin in antinociception: Its therapeutic applications. Curr Neuropharmacol 2012;10:167-78.|
|47||Caumo W, Torres F, Moreira NL Jr, Auzani JA, Monteiro CA, Londero G, et al. The clinical impact of preoperative melatonin on postoperative outcomes in patients undergoing abdominal hysterectomy. Anesth Analg 2007;105:1263-71.|
|48||Mowafi HA, Ismail SA. Melatonin improves tourniquet tolerance and enhances postoperative analgesia in patients receiving intravenous regional anesthesia. Anesth Analg 2008;107:1422-6.|
|49||Laste G, de Macedo IC, Ripoll Rozisky J, Ribeiro da Silva F, Caumo W, Torres IL. Melatonin administration reduces inflammatory pain in rats. J Pain Res 2012;5:359-62.|
|50||Wilhelmsen M, Amirian I, Reiter RJ, Rosenberg J, Gögenur I. Analgesic effects of melatonin: A review of current evidence from experimental and clinical studies. J Pineal Res 2011;51:270-7.|
|51||Samarkandi A, Naguib M, Riad W, Thalaj A, Alotibi W, Aldammas F, et al. Melatonin vs. midazolam premedication in children: A double-blind, placebo-controlled study. Eur J Anaesthesiol 2005;22:189-96.|
|52||Kain ZN, MacLaren JE, Herrmann L, Mayes L, Rosenbaum A, Hata J, et al. Preoperative melatonin and its effects on induction and emergence in children undergoing anesthesia and surgery. Anesthesiology 2009;111:44-9.|
|53||Fingland R, Cronin A, Keifer J, Shaheen J, Davies M, Bixler E. Postoperative REM sleep inhibition: Association with pain or cortisol? Reg Anesth Pain Med 1999;24:4.|
|54||Swaab DF, Fliers E, Partiman TS. The suprachiasmatic nucleus in the human brain in relation to sex, age and senile dementia. Brain Res 1985;342:37-44.|
|55||Cronin AJ, Keifer JC, Davies MF, King TS, Bixler EO. Melatonin secretion after surgery. Lancet 2000;356:1244-5.|
|56||Hanania M, Kitain E. Melatonin for treatment and prevention of postoperative delirium. Anesth Analg 2002;94:338-9.|
|57||Sultan SS. Assessment of role of perioperative melatonin in prevention and treatment of postoperative delirium after hip arthroplasty under spinal anesthesia in the elderly. Saudi J Anaesth 2010;4:169-73.|
|58||Al-Aama T, Brymer C, Gutmanis I, Woolmore-Goodwin SM, Esbaugh J, Dasgupta M. Melatonin decreases delirium in elderly patients: A randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2011;26:687-94.|
|59||Leon J, Acuna-Castroviejo D, Escames G, Tan DX, Reiter RJ. Melatonin mitigates mitochondrial malfunction. J Pineal Res 2005;38:1-9.|
|60||Kücükakin B, Gögenur I, Reiter RJ, Rosenberg J. Oxidative stress in relation to surgery: Is there a role for the antioxidant melatonin? J Surg Re. 2009;152:338-47.|
|61||Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P, et al. Effects of melatonin treatment in septic newborns. Pediatr Res 2001;50:756-60.|
|62||Kücükakin B, Lykkesfeldt J, Nielsen HJ, Reiter RJ, Rosenberg J, Gögenur I. Utility of melatonin to treat surgical stress after major vascular surgery-a safety study. J Pineal Res 2008;44:426-31.|
|63||Gitto E, Romeo C, Reiter RJ, Impellizzeri P, Pesce S, Basile M, et al. Melatonin reduces oxidative stress in surgical neonates. J Pediatr Surg 2004;39:184-9.|
|64||Kücükakin B, Wilhelmsen M, Lykkesfeldt J, Reiter RJ, Rosenberg J, Gögenur I. No effect of melatonin to modify surgical-stress response after major vascular surgery: A randomised placebo-controlled trial. Eur J Vasc Endovasc Surg 2010;40:461-7.|
|65||Altun, A, Ugur-Altun, B. Melatonin: Therapeutic and clinical utilization. Int J Clin Pract 2007;61:835-45.|
|66||NeLM news service. Sustained-release melatonin (Circadin) approved in EU. (Online). Available from: http://www.nelm.nhs.uk/en/NeLM-Area/News/494427/494566/494571. [Last cited on 2013 Jan 21]|
|67||Medscape reference. Melatonin (Herbs/Suppl). [Online]. Available from: http://reference.medscape.com/drug/n-acetyl-5-methoxytryptamine-pineal-hormone-melatonin-melatonin-344545 [Last cited on 2013 Jan 21].|
|68||Hartter S, Grozinger M, Weigmann H, Roschke J, Hiemke C. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther 2000;67:1-6.|